Compounded GLP-1 Advertising: What Compounders Need To Know NOW

The regulatory tone surrounding compounded GLP-1 products shifted decisively. What had been an aggressive but largely tolerated advertising environment is now under direct scrutiny from regulators, self-regulatory bodies and brand manufacturers. The National Advertising Division (NAD) recently issued a high-profile recommendation involving a telehealth company marketing compounded semaglutide, and the implications for compounding pharmacies are significant. The message is clear, i.e., advertising compounded GLP-1 products as if they are equivalent to FDA-approved drugs, or implying proven safety and efficacy, is no longer flying under the radar.

The NAD matter arose from a challenge brought by a branded manufacturer against a telehealth provider that marketed compounded semaglutide for weight loss. The challenger argued that the advertising conveyed express and implied claims about clinical effectiveness, safety and equivalence to FDA-approved products without